Breaking 14:00 Netanyahu and Arab Parties: 771 Shared Votes Raise Questions Over His Criticism of Eisenkot 13:30 The Agentic Web: Satya Nadella Predicts How AI Agents Will Reshape the Internet Economy 13:00 Morocco: Calls Grow to Expand Military Service for Young People Outside Education and Employment 12:30 Snapchat and AI: New Tools Make Augmented Reality Lens Development Easier for Creators 12:15 Morocco: Consumers Call for Stricter Controls on Sugar and Salt in Processed Foods 12:01 Alleged Call for Drone Strikes Against Moroccan Cities: DiplomAtlas Takes Action in French Courts 12:00 Saudi Arabia: Houthi Missile Attack Damages Riyadh's 80-Storey PIF Tower 11:45 Microsoft: CEO Satya Nadella Explains Why 60,000 Employees Were Offered Voluntary Exit Packages 11:30 US-Iran Tensions: Netanyahu Reportedly Urges Trump to Join New Military Strikes 11:15 Trump, Xi and Putin: An Unprecedented Trilateral Summit Makes History in China 11:00 Morocco's Textile Industry: Asian Competition and Weakening European Demand Threaten Growth 10:45 FIFA Presidency: Three Candidates Set for High-Stakes Election in Rabat in 2027 10:30 Trump–Vance Tensions Over Iran: Marco Rubio Emerges as a Potential 2028 Successor 10:15 Elon Musk Defends Jensen Huang: Nvidia’s Decision Compared to Benching Michael Jordan 10:00 Anthropic IPO: Company Makes Stock Market History With $81.3 Billion Offering at $83 Per Share 09:45 Trump Warns Iran: Alleged Chemical and Biological Weapons Plans Could Trigger Massive US Retaliation 09:30 Morocco: Amputee Football Team Targets World Cup Glory After Reaching Quarter-Finals in Mexico 09:15 Morocco: His Majesty King Mohammed VI's Vision Leads to Inauguration of International Hospital and University Complex in Dakhla 09:00 Morocco’s Defense Industry: 50,000 Jobs and 65% Export Revenue Targeted by 2035 08:45 Italy: Jewish Politician Resigns From Democratic Party After Dispute Over Antisemitism Law 08:30 Gaza Ceasefire Under Threat: Peace Council Accuses Israel and Hamas of Undermining the Truce 08:15 Morocco Weather Forecast: Temperatures to Reach 37°C in Aousserd on Thursday, November 19, 2026 23:00 Yassine Bounou Returns to Casablanca Roots; Inaugurates Ben Jdia’s First Football Pitch 22:00 British Hackers Face Justice: GTA 6 Leak and $11.6 Million Cryptocurrency Theft 21:30 Sam Altman on Jensen Huang: Why the AI Industry Is Hard to Imagine Without Him 21:00 Real Madrid: Arda Güler Extends Contract Until 2032 as Club Secures Turkish Star’s Future 20:30 Trump vs BBC: Florida Court Extends Deposition Deadline in $10 Billion Defamation Case 20:00 ECB: Stronger Cooperation Needed as AI-Powered Cyberattacks Continue to Rise 19:30 Iraq: Six More French Nationals Sentenced to Life Imprisonment Over ISIS Membership 19:00 Uber and Zipline: Drone Food Delivery Takes Off in Texas Ahead of Nationwide Expansion 18:30 Morocco: CNDH Faces Calls to Reveal Media Contracts and Public Spending 18:00 Morocco: Three Major National Milestones Celebrated at Diplomatic Reception in Bangladesh 17:30 China: Beijing Vows Retaliatory Measures Against New US Restrictions on Advanced Chip Exports 17:00 Ukraine War: Russia Accuses France of Direct Military Involvement in the Conflict 16:30 iPhone Repair Controversy: Apple Faces Major Legal Battle in Paris in June 2027 16:00 Morocco Celebrates the Birthday of Her Royal Highness Princess Lalla Hasnaa and Her Environmental Commitment 16:00 Nvidia: Halts Shipments of Hopper AI Chips to China Amid Rising Technology Tensions 16:00 His Majesty King Mohammed VI Sets 2035 Vision for Morocco's Defence Manufacturing Industry 15:30 France: Interior Minister Laurent Nuñez Faces Legal Complaint Over Alleged False Claims About Injured Police Officers 15:16 Morocco’s 71st Independence Day: Palestinian President Mahmoud Abbas Congratulates His Majesty King Mohammed VI 15:15 Morocco–UAE Security Cooperation: Abdellatif Hammouchi Signs Strategic Agreement With Dubai Police 15:00 European Union: Commission Proposes €45 Billion Loan to Support Ukraine in 2027 14:30 Morocco’s Direct Social Support Scheme: 1,460 Households Receive Employment Incentive Payments

Breakthrough Obesity Medication "Zepbound" Receives FDA Approval

Thursday 23 November 2023 - 13:00
Breakthrough Obesity Medication "Zepbound" Receives FDA Approval

In a groundbreaking development, the new medication "Zepbound" has been granted approval by the U.S. Food and Drug Administration (FDA), promising to address obesity by reducing weight by approximately 20% within a few months. Developed by the American pharmaceutical company Eli Lilly, Zepbound is set to be available in U.S. pharmacies by the end of the year.

Dr. Tayeb Hamdi, a physician and health policy and systems researcher, provides insights into this revolutionary pharmaceutical product. He emphasizes that Zepbound, based on the compound "Tirzepatide," has demonstrated its efficacy in significant weight reduction over a 17-month treatment period for specific categories of individuals struggling with overweight issues.

"The weight loss achieved by Zepbound, roughly 20%, is a substantial result for a medication and is even comparable to bariatric surgery," notes Dr. Hamdi. However, he cautions that while medications like Zepbound offer hope for individuals dealing with obesity, they are not a cure or a miraculous solution for the complex issues surrounding obesity and overweight conditions.

Dr. Hamdi clarifies that Zepbound is the second commercial name for the "Tirzepatide" molecule developed by Eli Lilly, following the first version named "Mounjaro," primarily designed for diabetes treatment. The Zepbound version, tailored with different packaging and dosages, aims to address obesity and overweight concerns.

It's important to note that Zepbound is not the first of its kind. Another medication, "Wegovy" (containing the "Semaglutide" molecule), has been on the market for several years, reducing weight by approximately 12%. Both molecules, Semaglutide and Tirzepatide, act through novel mechanisms for treating type 2 diabetes.

Dr. Hamdi explains that these molecules act on brain receptors, mimicking the action of two digestive hormones produced by the digestive system after a meal. One hormone helps reduce appetite and food intake, while the second enhances the body's breakdown of sugar and fats. Both molecules delay gastric emptying, providing the brain with a feeling of satiety. According to Dr. Hamdi, the superiority of Zepbound lies in its dual targeting of hormones, whereas Semaglutide targets only one.

However, Dr. Hamdi emphasizes the need for caution, particularly regarding potential misuse of the medication for weight loss in individuals without a formal indication. The benefit-risk balance has been studied only for specific indications, such as individuals with severe obesity (BMI over 30) or those with a BMI over 27 with at least one other risk factor, such as hypertension, hypercholesterolemia, or type 2 diabetes.

Regarding potential side effects, as with any medication, Zepbound, administered through injections, may cause common side effects such as nausea, vomiting, diarrhea, decreased appetite, constipation, upper abdominal discomfort, abdominal pain, and issues like intestinal obstruction, pancreatitis, and gastroparesis. Ongoing studies are exploring additional adverse effects.

On the issue of pricing, Eli Lilly has set the cost of Zepbound at $1,060 per month, slightly lower than its Danish competitor Wegovy, priced at $1,350 per month. Dr. Hamdi acknowledges that competition and the discovery of new molecules may influence pricing but underscores the cost as a significant challenge. Given that the treatment spans several months, there are concerns about maintaining weight loss after the treatment concludes.

Dr. Hamdi also alerts individuals tempted to purchase such medications to be wary of counterfeits. He highlights cases where patients were hospitalized after using counterfeit drugs bought online. With Zepbound entering the market, he anticipates an increase in scams and counterfeits that could pose significant health risks to unsuspecting users. He also emphasizes the health risks associated with the use of these products, even if authentic, without medical advice and documented medical indications.


  • Fajr
  • Sunrise
  • Dhuhr
  • Asr
  • Maghrib
  • Isha

Read more

This website, walaw.press, uses cookies to provide you with a good browsing experience and to continuously improve our services. By continuing to browse this site, you agree to the use of these cookies.